179 related articles for article (PubMed ID: 34693288)
1. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.
Weathers SP; Rood-Breithaupt J; de Groot J; Thomas G; Manfrini M; Penas-Prado M; Puduvalli VK; Zwingelstein C; Yung WKA
Neurooncol Adv; 2021; 3(1):vdab141. PubMed ID: 34693288
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Omuro A; Beal K; McNeill K; Young RJ; Thomas A; Lin X; Terziev R; Kaley TJ; DeAngelis LM; Daras M; Gavrilovic IT; Mellinghoff I; Diamond EL; McKeown A; Manne M; Caterfino A; Patel K; Bavisotto L; Gorman G; Lamson M; Gutin P; Tabar V; Chakravarty D; Chan TA; Brennan CW; Garrett-Mayer E; Karmali RA; Pentsova E
J Clin Oncol; 2018 Jun; 36(17):1702-1709. PubMed ID: 29683790
[TBL] [Abstract][Full Text] [Related]
5. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
[TBL] [Abstract][Full Text] [Related]
6. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Kim SJ; Lee HJ; Kim MS; Choi HJ; He J; Wu Q; Aldape K; Weinberg JS; Yung WK; Conrad CA; Langley RR; Lehembre F; Regenass U; Fidler IJ
Clin Cancer Res; 2015 Oct; 21(20):4630-41. PubMed ID: 26106074
[TBL] [Abstract][Full Text] [Related]
7. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
9. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
11. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Yust-Katz S; Liu D; Yuan Y; Liu V; Kang S; Groves M; Puduvalli V; Levin V; Conrad C; Colman H; Hsu S; Yung WK; Gilbert MR
Cancer; 2013 Aug; 119(15):2747-53. PubMed ID: 23633392
[TBL] [Abstract][Full Text] [Related]
12. Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma.
Woo JY; Yang SH; Lee YS; Lee SY; Kim J; Hong YK
J Korean Neurosurg Soc; 2015 Nov; 58(5):426-31. PubMed ID: 26713142
[TBL] [Abstract][Full Text] [Related]
13. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
14. Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Wang Y; Kong X; Guo Y; Wang R; Ma W
Medicine (Baltimore); 2017 Mar; 96(10):e6261. PubMed ID: 28272232
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma.
Allen BG; Bodeker KL; Smith MC; Monga V; Sandhu S; Hohl R; Carlisle T; Brown H; Hollenbeck N; Vollstedt S; Greenlee JD; Howard MA; Mapuskar KA; Seyedin SN; Caster JM; Jones KA; Cullen JJ; Berg D; Wagner BA; Buettner GR; TenNapel MJ; Smith BJ; Spitz DR; Buatti JM
Clin Cancer Res; 2019 Nov; 25(22):6590-6597. PubMed ID: 31427282
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
